The development of automated intermittent pumps has facilitated the use of regular intermittent bolus administration of epidural local anaesthetic drugs to maintain labour epidural analgesia. This mode of epidural drug delivery, when compared with conventional continuous epidural infusion (CEI), has been shown to improve pain scores, provide a longer duration of epidural analgesia, decrease the incidence of breakthrough pain (the onset of pain despite epidural maintenance), decrease the need for clinician-assisted epidural supplementation, decrease the total amount of local anaesthetic used and improve patient satisfaction [1] [2] [3] [4] . This may be due to a higher driving pressure being produced by the intermittent bolus-generated flow from all the orifices of a multi-orifice epidural catheter, resulting in better dispersion of infusate than can be achieved using a continuous infusion 5, 6 . The use of intermittent boluses results in a more uniform epidural block compared with a similar hourly rate of continuous infusion 1 .
Intermittent bolus volumes of 5 to 10 ml (given every 30 to 60 minutes) have been shown to be more effective than CEI for the maintenance of labour epidural analgesia [1] [2] [3] [4] , but the minimal bolus volume necessary to influence clinical outcome remains undetermined. Christiaens et al 7 found bolus volumes of 20 and 10 ml to be more effective than 4 ml. However, that study investigated single doses given for the initial treatment of pain rather than intermittent doses given for maintenance of labour epidural analgesia.
We hypothesised that the use of smaller volume boluses (≤5 ml) given at more frequent intervals could potentially be advantageous for the maintenance of labour epidural analgesia. Such a regimen could theoretically show a favourable pharmacokinetic profile and potentially reduce the risk of hypotension from the excessive dispersion of SuMMARY Delivery of local anaesthetics via automated intermittent bolus has been shown to improve epidural analgesia compared to delivery via continuous epidural infusion. However, the optimal bolus volume has not been investigated. This randomised, double-blind study compared the analgesic efficacy of automated intermittent bolus (volume 2.5 ml every 15 minutes) with that of a continuous epidural infusion (10 ml/hour) for the maintenance of labour epidural analgesia, to determine whether the advantages previously demonstrated for automated intermittent bolus over continuous epidural infusion are retained at this low bolus volume. With the approval of the Hospital Ethics Committee, we recruited 50 parturients who received combined spinal epidural analgesia with intrathecal ropivacaine 2 mg and fentanyl 15 µg. For epidural maintenance, participants were randomised to either the automated intermittent bolus group (2.5 ml automated intermittent epidural boluses of ropivacaine 0.1% plus fentanyl 2 µg/ml delivered over a two-minute period every 15 minutes) or the continuous epidural infusion group (continuous epidural infusion of ropivacaine 0.1% plus fentanyl 2 µg/ml at 10 ml/hour). The primary study outcome was the incidence of pain during labour that required management with supplemental epidural analgesia. There were no significant differences between the two regimens in terms of breakthrough pain (automated intermittent bolus 36% [9/25] vs continuous epidural infusion 32% [8/25] , P=0.77). At the doses used in this study, maintenance of labour analgesia using automated intermittent bolus at a bolus volume of 2.5 ml every 15 minutes does not decrease the incidence of breakthrough pain or improve analgesic efficacy compared to continuous epidural infusion. large boluses of local anaesthetic. It might minimise the risk of local anaesthetic toxicity and total spinal block in the event of intrapartum catheter migration. Yokoyama et al 8 found that a bolus as small as 1 ml had the potential to increase dispersion of local anaesthetic in the epidural space, contributing to the success of sequential epidural boluses. More frequent dosing intervals might also provide a profile of consistent analgesia, devoid of fluctuations.
In this study, we studied bolus volumes less than 5 ml, at more frequent intervals than previously described, to determine whether the advantages found for intermittent boluses over CEI were retained. Our primary aim was to compare the incidence of breakthrough pain in parturients who are given an automated intermittent bolus (AIB) administration of 2.5 ml of local anaesthesia at 15-minute intervals (total 10 ml/hour) with the incidence in parturients given a CEI of the same local anaesthetic at the same rate per hour. Breakthrough pain was chosen as the primary study outcome because of its clinical importance. It increases intrapartum pain scores, may decrease maternal satisfaction with epidural analgesia and increases the workload for anaesthetists in the delivery suite 4 . Our secondary outcomes were the effect on the duration of analgesia, maternal satisfaction and obstetric outcomes.
METHODS
This study conformed with Anaesthesia and Intensive Care's requirements for human trials, as described in the journal's Responsible Conduct of Research. It was conducted in accordance with the Declaration of Helsinki and with the approval of the hospital's institutional review board. Each participating parturient provided written informed consent (KK Hospital Institutional Review Board Registry, EC/2006/02/022).
Study population
In our previous study 4 , parturients who received combined spinal epidural analgesia and were maintained on a CEI of local anaesthetic had an incidence of breakthrough pain of 37%, whereas the incidence among parturients who received intermittent boluses of 5 ml every 30 minutes was 10%. The sample size was computed to detect a 30% difference in the incidence of breakthrough pain between the two study groups. Between 18 February and 19 March 2007, at request for pain relief, we recruited 50 healthy nulliparous parturients who presented at the Kandang Kerbau Women's and Children's Hospital (Singapore) maternity ward with cephalic presentation at ≥36 weeks of gestation. To be included, the parturient had to be in early, spontaneous labour (cervical dilation ≤5 cm). Exclusion criteria included contraindications to neuraxial block, multiple pregnancy, obstetric complications (e.g. pre-eclampsia, gestational diabetes or premature rupture of amniotic membranes) and parenteral opioid administration within the previous four hours.
Study protocol
This was a randomised, double-blind controlled clinical trial. We allocated the participants to the AIB and CEI groups using a sealed opaque envelope, which was opened after recruitment by the anaesthetist who was to perform the epidural. The parturient was blinded to the group allocation.
All baseline data were gathered by the attending nurse/midwife, who was also blinded to participant study group allocation. Following institutional protocol, we obtained baseline maternal anthropometric data (height and weight) and obstetric data including the use of oxytocin, cervical dilation and baseline systolic blood pressure and heart rate from the right brachial artery, using a non-invasive method (Dinamap, Critikon, FL, uSA). participants were interviewed by the attending nurse to establish a baseline numerical rating contraction pain score (0=no pain and 10=worst pain imaginable). The anaesthetist would then perform the epidural and set up the AIB/CEI pump. All outcome data were gathered by a blinded observer.
Each participant received combined spinal epidural analgesia at L3-L4 or L4-L5 while placed in the right lateral position. The single space, needlethrough-needle technique was performed with an 18 gauge Tuohy needle (Espocan, B. Braun, Melsungen, Germany), using loss of resistance to 3 ml of air and a 27 gauge pencil-point needle. The intrathecal drugs were ropivacaine 2 mg (Naropin, AstraZeneca, Sweden) and fentanyl 15 µg (David Bull Laboratories, Mulgrave, Victoria), injected over 15 seconds. The time of completion of the intrathecal injection was recorded as the starting time for the parturient's participation in the study (Time 0 ).
A multi-orifice epidural catheter was introduced 3 to 5 cm and tested with 3 ml of 1.5% lignocaine (Xylocaine, AstraZeneca, Sweden) to exclude intrathecal placement. participants who had blood or cerebrospinal fluid aspirated from the catheter or who experienced significant motor block (inability to flex the knees) were to be withdrawn from the study. Those not obtaining satisfactory pain relief (defined as a pain score >3, 20 minutes after receiving the intrathecal injection) were deemed to have a 'failed' block and were to be withdrawn, being replaced by another parturient via the randomisation sequence.
For maintenance of epidural analgesia, those randomised to AIB received 2.5 ml epidural boluses of 0.1% ropivacaine with fentanyl 2 µg/ml, infused over a two-minute period, every 15 minutes (Rythmic™ pump Micrel Medical Devices S.A., Pallini, Greece). The first bolus was given 7.5 minutes after the intrathecal injection. The participants randomised to CEI received 0.1% ropivacaine with fentanyl 2 µg/ml at 10 ml/hour, delivered by syringe pump (Infusion pump Syringe Terumo TE 311) and initiated immediately after the intrathecal injection.
A delivery suite nurse collected data at 5, 10, 15 and 30 minutes after the intrathecal injection and at 2, 4, 6, 8, 10, 12, 14 and 16 hours for those who had not delivered. Data included maternal blood pressure and heart rate, foetal heart rate, pain scores and side-effects (absent=0, present=1) of lower limb motor block, pruritus, shivering, hypotension, nausea, vomiting and foetal bradycardia.
We did not test the upper limit of sensory blockade as this can be equivocal in the presence of intrathecal lipophilic opioids 1 . We advised participants to inform the anaesthetist when contraction pain recurred (breakthrough pain). Breakthrough pain was defined as a failure to maintain effective analgesia intrapartum, namely pain necessitating the attending anaesthetist to provide additional epidural supplementation prior to delivery. At the time of complaint of breakthrough pain, the anaesthetist gave 5 ml boluses of 0.2% ropivacaine and the dose was included in the total requirement. The time of breakthrough pain was recorded as the completion of study participation for that participant (Time END ). Cervical dilation and use of oxytocin at the time of breakthrough pain were also recorded. If the pain score remained >3 despite 15 ml of 0.2% ropivacaine (three aliquots over 30 minutes), the epidural catheter was to be labelled as ineffective and the participant withdrawn and replaced via randomisation. If breakthrough pain did not occur, Time END was recorded as the time of neonatal delivery. The duration of effective analgesia was defined as from Time 0 to Time END .
During delivery, a reduction of systolic blood pressure >20% from baseline was treated with intravenous ephedrine 5 mg boluses. Nausea and vomiting were treated with metoclopramide. Foetal heart rate (from a continuous external cardio-tocogram) was assessed by the attending obstetrician who was blinded to the study group allocation. New changes suggestive of a non-reassuring foetal heart pattern within 30 minutes of the intrathecal injection were managed by left uterine displacement, supplemental oxygen and tocolytic drugs if uterine hyperactivity was suspected. The time of delivery, mode of delivery and neonate Apgar scores were recorded and neonates with low Apgar score were reviewed by a neonatologist.
Overall participant satisfaction with neuraxial analgesia was assessed using a 0 to 100 scale (0=very dissatisfied and 100=extremely satisfied) within two hours of delivery, by a member of the acute pain relief team who was unaware of study group allocation.
Statistical analysis
The Student's t-test was used to analyse parametric data and the Mann-Whitney test was used to analyse non-parametric data. The chi-square test with Yates correction was used to analyse nominal data. As a significant number of participants were expected to deliver before breakthrough pain occurred, the duration of time from Time 0 to the time of neonate delivery was computed as censored data. In the comparison of duration of effective analgesia, Kaplan-Maier survival analysis was used and the mean time to intervention for breakthrough pain was analysed using a log-rank test. All data and statistical analyses were managed using SpSS version 9 software (Chicago, IL, uSA).
RESuLTS
We recruited 51 parturients into the study, of whom 25 were randomised to the AIB group and 26 were randomised to the CEI group (1 participant subsequently discontinued) ( Figure 1 ). There were no significant differences between the two groups regarding anthropometric and pre-analgesic obstetric data ( Table 1) . None of the participants experienced an ineffective block and all 50 participants who completed the study were analysed.
There were no significant differences between the AIB and CEI groups regarding the percentage that experienced breakthrough pain ( Table 2) . There was no difference between groups regarding the total consumption of ropivacaine (including local anaesthetic administered for breakthrough pain) or in the time-weighted consumption of local anaesthetic administered epidurally from induction of combined spinal epidural analgesia to the time of delivery (AIB 11.39±2.55 ml/hour vs CEI 11.07±7.73 ml/hour, P=0.66). There was no difference between groups regarding the mean duration of labour (Table 2 ). There were also no differences between groups regarding participant satisfaction with the epidural analgesia, sideeffects, haemodynamic profile, mode of delivery or neonatal outcomes. Two participants in the AIB group and three participants in the CEI group experienced foetal bradycardia that did not require uterine relaxation or caesarean delivery. They were managed conservatively in the left lateral position with oxygen supplementation.
The mean time to breakthrough pain in the two groups was not significantly different (Table 3 ). There were also no differences between groups regarding participant pain scores, sensory level, use of oxytocin or cervical dilation at the time of breakthrough pain ( Table 3 ).
There were no differences between groups regarding intrapartum pain scores (Table 4 and Figure 2 ). Taking into account participants who had (Figure 3 ).
DISCuSSION
Our results showed that epidural local anaesthetics administered for the maintenance of labour analgesia via regular AIB administration at a bolus volume of 2.5 ml every 15 minutes did not reduce the incidence of breakthrough pain or the need for supplemental analgesia compared to CEI of the same solution at the same hourly rate. Thus, a bolus volume less than 5 ml did not retain the advantages that have been demonstrated for bolus volumes ≥5 ml [1] [2] [3] [4] . Given that the bolus volume used in our current study was relatively small and the interval between the intermittent doses was short, it is possible that the dynamics of the intermittent dosing approximated that of a continuous infusion. Since both the AIB and CEI groups received 10 ml/hour of the same local anaesthetic, the approximation of continuous infusion by the AIB would result in the delivery of the same local anaesthetic in the same quantity at the same rate in both groups, so it might be expected that there would be no difference in outcomes. This study suggests that a bolus volume of more than 2.5 ml is required for the desired clinical outcome and use of smaller volumes, even if administered at a higher frequency, cannot be recommended. Apart from volume, the speed at which the infusion bolus is delivered and the pressure generated in the epidural space also affects dispersion. During the continuous infusion of a drug under low pressure, the infusate discharges predominantly from the proximal hole of the catheter with minimal flow from the distal hole, which effectively converts a multi-orifice catheter into a single-orifice catheter 9 . D'Angelo et al 10 and Kaynar 11 both demonstrated that single-orifice catheters are associated with inadequate epidural analgesia more often than are multi-orifice catheters, so the nature of flow may have influenced the outcome of this study, in which the 2.5 ml boluses were infused over two minutes. Theoretically, intermittent boluses injected at higher pressure should aid more widespread and uniform epidural solution dispersion. Future studies should evaluate the effect of pressure and speed of bolus injection, which were not investigated in this study.
In this study, we deliberately programmed the first intermittent bolus at 7.5 minutes after completion of the intrathecal injection but started CEI immediately, to reduce the likelihood of a disparity in drug consumption. Irrespective, the study did not demonstrate a reduction in total local anaesthetic use in the AIB group.
The maternal satisfaction scores in this study were very high, despite the high incidence of breakthrough pain (more than 30% in both groups). This supports the fact that factors other than pain intensity or breakthrough pain affect satisfaction with pain relief. All participants were closely monitored and frequently reviewed by the caregivers, which may have enhanced the overall analgesic experience.
Entry criteria included care in a hospital maternity ward and request for epidural analgesia, so the results should be generalisable to other parturients in similar circumstances.
In conclusion, as a method of maintaining epidural analgesia during labour after a combined spinal epidural technique, our study found that automated intermittent boluses at a volume of 2.5 ml, given at 15-minute intervals, did not improve analgesic efficacy compared with a continuous epidural infusion of the same solution at the same hourly rate.
